Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations
for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus …

PURPOSE Nivolumab received US Food and Drug Administration approval as a single
agent or in combination with ipilimumab in patients with microsatellite instability …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Guillain-Barré syndrome is the most common cause of acute flaccid paralysis worldwide.
Most patients present with an antecedent illness, most commonly upper respiratory tract …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the
fourth most common malignancy and the second leading cause of tumor-related death …

Context Treatment of metastatic urothelial carcinoma is currently undergoing a rapid
evolution. Objective This overview presents the updated European Association of Urology …